Kaken Pharmaceutical Balance Sheet

Financials in millions JPY. Fiscal year is April - March.

Millions JPY. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021
Cash & Equivalents	36,847	54,093	50,625	59,561	61,025	63,706
Short-Term Investments	8,991	15,992	14,699	14,699	13,599	13,599
Cash & Short-Term Investments	45,838	70,085	65,324	74,260	74,624	77,305
Cash Growth	-42.52%	7.29%	-12.03%	-0.49%	-3.47%	5.43%
Receivables	27,519	21,178	23,744	19,268	20,260	20,549
Inventory	20,648	19,020	17,167	15,563	14,980	15,197
Other Current Assets	2,516	1,094	739	812	749	611
Total Current Assets	96,521	111,377	106,974	109,903	110,613	113,662
Property, Plant & Equipment	28,687	27,629	25,355	25,498	25,734	25,020
Long-Term Investments	19,260	28,061	29,241	20,312	18,871	22,447
Goodwill	13,592	14,035	-	-	-	-
Other Intangible Assets	5,486	5,254	7,462	6,741	8,236	625
Long-Term Deferred Tax Assets	-	4,065	2,590	3,873	1,725	1,577
Other Long-Term Assets	12,894	1	1	1	2	1
Total Assets	176,440	190,422	171,623	166,328	165,181	163,332
Accounts Payable	9,917	8,322	7,099	6,219	5,939	8,569
Accrued Expenses	542	2,385	1,639	1,561	1,394	1,450
Short-Term Debt	3,850	3,850	3,850	3,850	3,850	3,850
Current Income Taxes Payable	24	13,596	4,222	7,828	5,979	5,294
Other Current Liabilities	9,275	2,201	2,214	1,380	1,887	2,113
Total Current Liabilities	23,608	30,354	19,024	20,838	19,049	21,276
Pension & Post-Retirement Benefits	4,945	4,954	6,393	6,349	5,039	5,376
Long-Term Deferred Tax Liabilities	1,514	1,514	1,947	1,771	2,229	-
Other Long-Term Liabilities	565	966	505	535	540	423
Total Liabilities	30,632	37,788	27,869	29,493	26,857	27,075
Common Stock	23,853	23,853	23,853	23,853	23,853	23,853
Additional Paid-In Capital	11,406	12,932	11,462	11,406	11,406	11,406
Retained Earnings	124,879	135,242	128,506	126,135	126,347	122,462
Treasury Stock	-23,775	-28,233	-28,613	-30,026	-28,714	-26,304
Comprehensive Income & Other	9,445	8,840	8,546	4,889	4,854	4,840
Total Common Equity	145,808	152,634	143,754	136,257	137,746	136,257
Minority Interest	-	-	-	578	578	-
Shareholders' Equity	145,808	152,634	143,754	136,835	138,324	136,257
Total Liabilities & Equity	176,440	190,422	171,623	166,328	165,181	163,332
Total Debt	3,850	3,850	3,850	3,850	3,850	3,850
Net Cash (Debt)	41,988	66,235	61,474	70,410	70,774	73,455
Net Cash Growth	-44.68%	7.75%	-12.69%	-0.51%	-3.65%	5.73%
Net Cash Per Share	1108.79	1735.63	1629.01	1874.05	1863.55	1903.47
Filing Date Shares Outstanding	37.87	37.87	37.87	37.47	37.79	38.32
Total Common Shares Outstanding	37.87	38.4	37.87	37.47	37.82	38.32
Working Capital	72,913	81,023	87,950	89,065	91,564	92,386
Book Value Per Share	3850.39	3974.44	3796.01	3636.14	3642.30	3555.92
Tangible Book Value	126,730	133,345	136,292	129,516	129,510	135,632
Tangible Book Value Per Share	3346.60	3472.18	3598.97	3456.25	3424.53	3539.61

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.